Massard C - Search Results

1

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic.

Bayle A, Baldini C, Martin-Romano P, Michot JM, Champiat S, Bahleda R, Gazzah A, Marabelle A, Verlingue L, Geraud A, Morel D, Michiels S, Hollebecque A, Albiges L, Besse B, Soria JC, Massard C, Barlesi F, Postel-Vinay S. Bayle A, et al. Among authors: massard c. Cancer Cell. 2021 Aug 9;39(8):1039-1041. doi: 10.1016/j.ccell.2021.06.010. Epub 2021 Jun 18. Cancer Cell. 2021. PMID: 34197735 Free PMC article. No abstract available.

2

[Cannabis and cancer].

Vignot S, Besse B, de la Motte Rouge T, Massard C, Spano JP, Karila L. Vignot S, et al. Among authors: massard c. Bull Cancer. 2006 Feb;93(2):163-70. Bull Cancer. 2006. PMID: 16517414 Free article. Review. French.

3

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Among authors: massard c. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

4

Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Ferté C, Massard C, Moldovan C, Desruennes E, Loriot Y, Soria JC. Ferté C, et al. Among authors: massard c. Invest New Drugs. 2009 Dec;27(6):583-5. doi: 10.1007/s10637-009-9227-7. Epub 2009 Feb 17. Invest New Drugs. 2009. PMID: 19221694

5

From theoretical synergy to clinical supra-additive toxicity.

Soria JC, Massard C, Izzedine H. Soria JC, et al. Among authors: massard c. J Clin Oncol. 2009 Mar 20;27(9):1359-61. doi: 10.1200/JCO.2008.20.8595. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224836 No abstract available.

6

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.

Gombos A, Izzedine H, Besse B, Massard C, Brocheriou I, Bahleda R, Soria JC. Gombos A, et al. Among authors: massard c. Invest New Drugs. 2010 Feb;28(1):102-5. doi: 10.1007/s10637-009-9247-3. Epub 2009 Apr 3. Invest New Drugs. 2010. PMID: 19343274

7

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.

Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC. Domont J, et al. Among authors: massard c. Invest New Drugs. 2010 Apr;28(2):199-202. doi: 10.1007/s10637-009-9249-1. Epub 2009 Apr 8. Invest New Drugs. 2010. PMID: 19352594 No abstract available.

8

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

Bahleda R, Massard C, Soria JC, Izzedine H, Cohen A, Ederhy S. Bahleda R, et al. Among authors: massard c. Invest New Drugs. 2010 Jun;28(3):350-2. doi: 10.1007/s10637-009-9252-6. Epub 2009 Apr 25. Invest New Drugs. 2010. PMID: 19396400

9

QT interval prolongation among patients treated with angiogenesis inhibitors.

Ederhy S, Cohen A, Dufaitre G, Izzedine H, Massard C, Meuleman C, Besse B, Berthelot E, Boccara F, Soria JC. Ederhy S, et al. Among authors: massard c. Target Oncol. 2009 Apr;4(2):89-97. doi: 10.1007/s11523-009-0111-3. Epub 2009 May 6. Target Oncol. 2009. PMID: 19418112 Review.

10

Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice.

Massard C, Tran Ba Loc P, Haddad V, Pignon JP, Girard P, Monnet I, Trédaniel J, Besse B, Soria JC. Massard C, et al. J Thorac Oncol. 2009 Dec;4(12):1504-10. doi: 10.1097/JTO.0b013e3181bbf1c9. J Thorac Oncol. 2009. PMID: 19745763 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

464 results

Search Page